IN VITRO ANTIMYCOTIC EVALUATION AND PRELIMINARY COMBINATORIAL STUDIES OF IBUPROFEN WITH STANDARD ANTIFUNGAL DRUGS AGAINST ASPERGILLUS SPP.
Objective: The prevalence of invasive mycoses is increased in the immunocompromised patients with an increase in resistance developed againstcurrent antifungal drugs. This has led to the need for discovering novel combinations of the antifungal drugs to combat against resistant pathogenic spp.This study mainly targets to evaluate the antifungal activity of ibuprofen (IBU) alone and in combination with the standard antifungal drugs (polyenesand azoles) against eight isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger.
Methods: The study was performed using the disc diffusion assay (DDA), microbroth dilution assay and spore germination inhibition assay. Moreover,cytotoxicity was checked by heamolytic assay.
Results: Minimum inhibitory concentration (MIC) of IBU against A. fumigatus and A. flavus using DDA is found to be in the range of 250-275 Î¼g/disc while for A. niger isolates, the range was 500-575 Î¼g/disc. Likewise, by broth microdilution assay and spore germination inhibitory assay, MICdetermined, were in the range of 500-750 Î¼g/ml against A. fumigatus and A. flavus while for A. niger, it was 1000-1500 Î¼g/ml.
Conclusion: IBU demonstrated its antimycotic potential against all the eight isolates of Aspergillus spp. Moreover, preliminary combinatorialevaluation of IBU with the standard antifungal drugs reported by DDA revealed an increase in zone of inhibition as compared to the drugs alone.Further research regarding the confirmation of synergistic interaction between the selected drugs is in progress.
with invasive aspergillosis from the PATH Alliance registry. J Infect 2012;65(5):453â€‘64.
2. Naaraayan A, Kavian R, Lederman J, Basak P, Jesmajian S. Invasive pulmonary aspergillosis - Case report and review of literature.
J Community Hosp Intern Med Perspect 2015;5(1):26322.
3. Nandhini SU, Bharathy PJ, Rekha S. Antifungal compounds from marine Streptomyces. Int J Pharm Pharm Sci 2015;7(1):207-9.
4. Ruhil S, Balhara M, Dhankhar S, Kumar M, Kumar V, Chhillar AK. Advancement in infection control of opportunistic pathogen (Aspergillus Spp.): Adjunctive agents. Curr Pharm Biotechnol 2013;14(2):226-32.
5. Li-Juan L, Wei C, Hui X, Zhe W, Ruo-yu L, Wei L. Antifungal activity of ibuprofen against Aspergillus species and its interaction with
common antifungal drugs. Chin Med J 2010;123 Suppl 19:2701-5.
6. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: A critical assessment. Clin Ther 2000;22(5):500-48.
7. Costa-de-Oliveira S, Miranda IM, Silva-Dias A, Silva AP, Rodrigues AG, Pina-Vaz C. Ibuprofen potentiates the in vivo antifungal
activity of fluconazole against Candida albicans murine infection. Antimicrob Agents Chemother 2015;59(7):4289-92.
8. Venturini TP, Rossato L, Spader TB, Tronco-Alves GR, Azevedo MI, Weiler CB, et al. In vitro synergisms obtained by
amphotericin B and voriconazole associated with non-antifungal agents against Fusarium Spp. Diagn Microbiol Infect Dis
9. Medeiros CI, Silva DD, Filho GG, Filho AA, Lima EE. Activity anti-c. Tropicalis and effects of the combination of (s)-(-)-citronellal with four antifungal applied in vulvovaginal candidiasis. Int J Pharm Pharm Sci 2016;8(8):347-51.
10. Ricardo E, Costa-de-Oliveira S, Dias AS, Guerra J, Rodrigues AG, Pina-Vaz C. Ibuprofen reverts antifungal resistance on Candida
albicans showing overexpression of CDR genes. FEMS Yeast Res 2009;9(4):618-25.
11. Chhillar AK, Arya P, Mukherjee C, Kumar P, Yadav Y, Sharma AK, et al. Microwave-assisted synthesis of antimicrobial dihydropyridines and tetrahydropyrimidin-2-ones: Novel compounds against aspergillosis. Bioorg Med Chem 2006;14(4):973-81.
12. Rex JH, Cooper CR Jr, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system.Antimicrob Agents Chemother 1995;39(4):906-9.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.